Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 14

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 14
---
X (107) (41) (41) (20) (5) Transaction and restructuring costs 266 335 127 57 (253) Free Cash Flow pre - M&A 1 Note: All figures are presented on a consolidated basis (including Biotest) 1 FCF definition and reconciliation to the Cash Flow Statement in slide 39 in the Annex 2 FCF conversion = FCF pre - M&A/Adj. EBITDA Q2’24 Q3’24 FY ’24 Q1’24 Q4’24 Free Cash Flow Generation • Improved EBITDA conversion into FCF • CPL reduction • Granular inventory and net working capital management • Yield improvements • Rationalizing and re - scheduling CAPEX plans • Lower restructuring and transaction costs • FCF definition and reconciliation to the Cash Flow Statement in slide 39 (Annex) Free Cash Flow Strong EBITDA Performance Backed by Granular Net Working Capital and Capex Management Delivering FCF Out Performance 15% Free Cash Flow Conversion Rate 2

- 17 - Q4 2024 Results Introductory Remarks Business Performance Financials Final remarks Annex Note: All figures are presented on a consolidated basis (including Biotest), and at constant currency (cc), excluding exchang e r ate fluctuations over the period. See Annex for reconciliations. Figures for 2022 have been re - expressed according to the Inside Information released on July 30, 2024 Inventory (in million EUR except DOI) 310 237 278 307 309 294 0 1,000 2,000 3,000 4,000 2019 2020 2021 2022 2023 2024 Inventory (in million EUR) Inventory turnover (in days) Inventory and Capex Inventory Management Benefiting FCF Generation Considerably; Elevated CAPEX and Capitalized IT and R&D Levels as % of Revenues to Subside 8% 7% 6% 6% 5% 9% (incl. extraordinary) 5% -6% -4% -2% 0% 2% 4% 6% 8% 10% 0 100 200 300 400 500 600 700 800 2019 2020 2021 2022 2023 2024 Extraordinary CAPEX (primarily ImmunoTek) R&D and IT Growth CAPEX Maintenance CAPE